For patients with symptomatic ailment requiring therapy, ibrutinib is usually proposed depending on 4 phase III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 and other typically applied CIT combinations, namely FCR, bendamustine in addition rituximab and chlorambucil moreover obinutuzumab (ClbO).107–109 Ibrutinib